MedX Health Evaluating Options for $1M Financing
21 Mayo 2012 - 9:12PM
PR Newswire (Canada)
$1,000,000 Dollar Growth Financing to Accelerate the Global
Expansion of MoleMate Skin Cancer Imaging Sales and Marketing
Programs MISSISSAUGA, ON, May 22, 2012 /CNW/ - MedX Health Corp.,
(TSXV.MDX) with worldwide revenues in drug free, non-invasive low
level laser light therapy and light imaging systems, announced
today that they are withdrawing the original private placement
announced on April 2, 2012 and evaluating a number of financing
vehicles to raise up to $1,000,000 to accelerate the expansion of
the MoleMate skin cancer imaging sales and marketing programs.
"This growth financing will allow MedX to deploy the capital needed
to further accelerate our sales and marketing programs in North
America, Europe, Australia, and entry into new geographies. As the
leading innovator in this emerging market space, this funding
will go a long way in helping us share the company's vision of
becoming the premier provider of a better way to identify skin
cancer early, without a surgical biopsy, and will give us the
ability to immediately implement our ambitious growth plans," said
Steve Guillen, President & CEO. Learn More The website
www.simsys-molemate.com contains additional information on MoleMate
and SIMSYS, including information on the technology behind these
products, as well as product demos, and information on how other
physicians have integrated the skin cancer imaging system into
their practice. About MedX Health Corp. MedX is a twelve (12) year
old Canadian company, headquartered in Mississauga, Ontario
(Toronto), and is a global leader in the design, manufacturing and
distribution of quality low level laser and light therapy
technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine,
providing patients with drug free and non-invasive treatment of
tissue damage and pain. MedX laser and light products are FDA
approved, Health Canada cleared, and CE Mark approved for use in
North America as well as the European Union. MedX acquired
the worldwide assets related to MoleMate for the early detection of
skin cancer in June 2011. This press release does not constitute an
offer of any securities for sale. This press release contains
certain forward-looking statements within the meaning of applicable
Canadian securities legislation. These forward-looking
statements involve certain risks and uncertainties that could cause
actual results to differ, including, without limitation, the
company's limited operating history and history of losses, the
inability to successfully obtain further funding, the inability to
raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete
the proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the
company's projections or forward-looking statements. All
forward-looking statements in this press release are based on
information available to the company as of the date hereof, and the
company undertakes no obligation to update forward-looking
statements to reflect events or circumstances occurring after the
date of this press release. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. MedX Health Corp.
CONTACT: Investors:Steve GuillenPresident and Chief Executive
OfficerMedX Health Corp. investor@medxhealth.comPhone: (905)
670-4428
Copyright
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024